To directly test if increased XIAP-NFκB survival signaling can suppress efficacy of immunotherapy, we tested the FDA approved EGFR-specific monoclonal antibody (cetuximab), widely used in cancer therapy, in in vitro antibody-dependent cellular cytotoxicity (ADCC) assays and in in vivo tumor growth kinetic analysis of IBC cells with differential apoptotic capability when implanted orthotopically in the mammary fat pad of mice with functional NK activity. This evidence concerns the gene EGFR and neoplasm.